AB0 BLOOD TYPES AND MALIGNANT COLORECTAL NEOPLASMS OF DIFFERENT LOCATION: A RETROSPECTIVE ANALYSIS OF 1570 CASES
- Authors: Kerimov R.A.1, Seksenbayev B.D.2, Galimov O.V.3, Nurmashev B.K.2, Znanteyev M.E.1
-
Affiliations:
- Khoja Akhmet Yassawi International Kazakh-Turkish University
- South Kazakhstan State Pharmaceutical Academy
- Bashkortostan State Medical University
- Issue: Vol 72, No 6 (2017)
- Pages: 458-465
- Section: ONCOLOGY: CURRENT ISSUES
- Published: 08.11.2017
- URL: https://vestnikramn.spr-journal.ru/jour/article/view/884
- DOI: https://doi.org/10.15690/vramn884
- ID: 884
Cite item
Full Text
Abstract
Background: AB0 blood type antigens are unequally expressed in different portions of the colon resulting in so-called proximal-distal gradient. In most research studies considering the link between blood types and colorectal cancer, this gradient has not been taken into account. In the present context the findings of such studies are not convincing, no evidence-based results are reflected in literature. Valid studies of this association require antigenic distribution of the colon and malignant tumor location to be taken into account.
Aim: To assess the possible relation between AB0 blood type antigens and malignant tumors located in different parts of the large intestine.
Materials and methods: We performed a case-control study with retrospective analysis of medical records on patients with the presented disease (cases) and patients who did not suffer from it (controls). Required data was obtained from regional oncological centers of South Kazakhstan, Karaganda, East Kazakhstan, and Mangystau regions. Every third case of colorectal cancer registered in 2011−2016 years was included in the survey. The studied association was estimated by means of a chi-square test. A multinomial logistic regression was used to calculate the odds ratio (OR) with confounding risk factors to be taken into account. Shares of the samples were compared by means of Student’s t-test. A critical level of statistical significance (p-value) was considered to be 0.05.
Results: Each group included 1570 patients. Gender, age, and ethnic distribution did not differ statistically in cases and controls (p>0.4 for all comparisons). When blood type distributions were compared between groups regardless of tumor locations, any significant difference was not revealed (p=0.141). When similar calculations were applied to specific parts of the large intestine, the association between 0 blood type and malignancies of distal portions of the colon was demonstrated (p=0.0002). When we calculate the odds ratio for the disease development in the colon parts (using a multinomial logistic regression), the following results were obtained: 1.518 (p=0.004) for 0, 0.781 (p=0.099) for A, 0.785 (p=0.143) for B, and 0.965 (p=0.884) for AB blood types.
Conclusions: The results of the present study revealed a statistical correlation between the 0 blood type and malignant tumors located in the distal portions of the colon.About the authors
R. A. Kerimov
Khoja Akhmet Yassawi International Kazakh-Turkish University
Author for correspondence.
Email: kir-2004@list.ru
ORCID iD: 0000-0001-6156-0958
Магистр медицины, PhD докторант медицинского факультета МКТУ им. Х.А. Ясави.
161200, Туркестан, пр-кт Б. Саттарханова, д. 29
КазахстанB. D. Seksenbayev
South Kazakhstan State Pharmaceutical Academy
Email: rektorukgma@mail.ru
ORCID iD: 0000-0003-2556-2360
Shymkent Казахстан
O. V. Galimov
Bashkortostan State Medical University
Email: galimovov@mail.ru
ORCID iD: 0000-0003-4832-1682
Ufa Россия
B. K. Nurmashev
South Kazakhstan State Pharmaceutical Academy
Email: bekaidar@bk.ru
ORCID iD: 0000-0003-3949-2543
Shymkent Казахстан
M. E. Znanteyev
Khoja Akhmet Yassawi International Kazakh-Turkish University
Email: zhanteev1963@mail.ru
ORCID iD: 0000-0002-5387-3476
Кандидат медицинских наук, доцент кафедры травматологии, ортопедии и онкологии МКТУ им. Х.А. Ясави.
161200, Туркестан, проспект Б. Саттарханова, д. 29
References
- Hakomori S. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta. 1999;1473(1):247–266. doi: 10.1016/S0304-4165(99)00183-X.
- Yuan M, Itzkowitz SH, Palekar A, et al. Distribution of blood group antigens A, B, H, Lewisa, and Lewisb in human normal, fetal, and malignant colonic tissue. Cancer Res. 1985;45(9):4499–4511.
- Aird I, Bental HH, Roberts JA. A relationship between cancer of stomach and the ABO blood groups. BMJ. 1953;1(4814):799–801. doi: 10.1136/bmj.1.4814.799.
- Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 2009;101(6):424–431. doi: 10.1093/jnci/djp020.
- Khalili H, Wolpin BM, Huang ES, et al. ABO blood group and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(5):1017–1020. doi: 10.1158/1055-9965.EPI-10-1250.
- Halvorsen TB. ABO blood groups, rhesus types, and colorectal adenocarcinoma. A retrospective study of 747 cases. Scand J Gastroenterol. 1986;21(8):979–983. doi: 10.3109/00365528608996408.
- Slater G, Itzkowitz S, Azar S, Aufses AH, Jr. Clinicopathologic correlations of ABO and Rhesus blood type in colorectal cancer. Dis Colon Rectum. 1993;36(1):5–7. doi: 10.1007/bf02050293.
- Dean L. ABO Blood Group. In: Pratt V, McLeod H, Dean L, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012 [cited 2017 Sep 13]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK100894/.
- Ashkani J, Naidoo KJ. Glycosyltransferase gene expression profiles classify cancer types and propose prognostic subtypes. Sci Rep. 2016;6:26451. doi: 10.1038/srep26451.
- Boland CR. Chronic inflammation, colorectal cancer and gene polymorphisms. Dig Dis. 2010;28(4–5):590–595. doi: 10.1159/000320053.
- Rubin DC, Shaker A, Levin MS. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol. 2012;3:107. doi: 10.3389/fimmu.2012.00107.
- Hu T, Li LF, Shen J, et al. Chronic inflammation and colorectal cancer: the role of vascular endothelial growth factor. Curr Pharm Des. 2015;21(21):2960–2967. doi: 10.2174/1381612821666150514104244.